1. Academic Validation
  2. Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5

Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5

  • Nucleic Acids Res. 2015 Jan;43(1):373-84. doi: 10.1093/nar/gku1276.
Yue Huang 1 Jingli Yan 2 Qi Li 1 Jiafei Li 1 Shouzhe Gong 1 Hu Zhou 1 Jianhua Gan 3 Hualiang Jiang 4 Gui-Fang Jia 2 Cheng Luo 4 Cai-Guang Yang 5
Affiliations

Affiliations

  • 1 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 2 Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China.
  • 3 School of Life Sciences, Fudan University, Shanghai 200433, China.
  • 4 State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • 5 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China yangcg@simm.ac.cn.
Abstract

Two human demethylases, the fat mass and obesity-associated (FTO) Enzyme and ALKBH5, oxidatively demethylate abundant N(6)-methyladenosine (m(6)A) residues in mRNA. Achieving a method for selective inhibition of FTO over ALKBH5 remains a challenge, however. Here, we have identified meclofenamic acid (MA) as a highly selective inhibitor of FTO. MA is a non-steroidal, anti-inflammatory drug that mechanistic studies indicate competes with FTO binding for the m(6)A-containing nucleic acid. The structure of FTO/MA has revealed much about the inhibitory function of FTO. Our newfound understanding, revealed herein, of the part of the nucleotide recognition lid (NRL) in FTO, for example, has helped elucidate the principles behind the selectivity of FTO over ALKBH5. Treatment of HeLa cells with the ethyl ester form of MA (MA2) has led to elevated levels of m(6)A modification in mRNA. Our collective results highlight the development of functional probes of the FTO Enzyme that will (i) enable future biological studies and (ii) pave the way for the rational design of potent and specific inhibitors of FTO for use in medicine.

Figures